Task: Table-QA (source dataset: FinQA)

Task: 
You are given a table containing structured data and a natural language question referring to the table. Your goal is to analyze the table and provide an accurate and concise answer based on the given data.

Instructions:
1. Understand the Table: Examine the structure, headers, and data in the table. Identify relevant columns and rows related to the question.
2. Interpret the Question: Determine whether the question requires direct retrieval, aggregation, comparison, sorting, filtering, or inference.
3. Extract the Answer: Use logical reasoning and numerical operations (if necessary) to derive the correct response from the table.
4. Format the Answer: No explanation, return the answer in a structured JSON format: {"answer": <answer>}. If the question cannot be answered due to missing or ambiguous data, return a JSON response with {"answer": null}.

Table:
| cash portion of consideration                           | $ 2094800   |
|:--------------------------------------------------------|:------------|
| fair value of securities issued                         | 3671500     |
| fair value of vested options exchanged                  | 241400      |
| fair value of cytyc 2019s outstanding convertible notes | 125000      |
| direct acquisition costs                                | 24200       |
| total estimated purchase price                          | $ 6156900   |

Question:
what percent of the purchase was in cash?


pre_text: table of contents hologic , inc .
notes to consolidated financial statements ( continued ) ( in thousands , except per share data ) cytyc , headquartered in marlborough , massachusetts , is a diversified diagnostic and medical device company that designs , develops , manufactures , and markets innovative and clinically effective diagnostics and surgical products .
cytyc products cover a range of cancer and women 2019s health applications , including cervical cancer screening , prenatal diagnostics , treatment of excessive menstrual bleeding and radiation treatment of early-stage breast cancer .
upon the close of the merger , cytyc shareholders received an aggregate of 132038 shares of hologic common stock and approximately $ 2094800 in cash .
in connection with the close of the merger , the company entered into a credit agreement relating to a senior secured credit facility ( the 201ccredit agreement 201d ) with goldman sachs credit partners l.p .
and certain other lenders , in which the lenders committed to provide , in the aggregate , senior secured financing of up to approximately $ 2550000 to pay for the cash portion of the merger consideration , repayment of existing debt of cytyc , expenses relating to the merger and working capital following the completion of the merger .
as of the closing of the merger , the company borrowed $ 2350000 under this credit agreement .
see note 5 for further discussion .
the aggregate purchase price of approximately $ 6156900 included $ 2094800 in cash ; 132038 shares of hologic common stock at an estimated fair value of $ 3671500 ; 16465 of fully vested stock options granted to cytyc employees in exchange for their vested cytyc stock options , with an estimated fair value of approximately $ 241400 ; the fair value of cytyc 2019s outstanding convertible notes assumed in the merger of approximately $ 125000 ; and approximately $ 24200 of direct acquisition costs .
there are no potential contingent consideration arrangements payable to the former cytyc shareholders in connection with this transaction .
the company measured the fair value of the 132038 shares of the company common stock issued as consideration in connection with the merger under eitf 99-12 .
the company determined the measurement date to be may 20 , 2007 , the date the transaction was announced , as the number of shares to be issued according to the exchange ratio was fixed without subsequent revision .
the company valued the securities based on the average market price a few days before and after the measurement date .
the weighted average stock price was determined to be $ 27.81 .
( i ) purchase price the purchase price is as follows: .
post_text: source : hologic inc , 10-k , november 24 , 2009 powered by morningstar ae document research 2120 the information contained herein may not be copied , adapted or distributed and is not warranted to be accurate , complete or timely .
the user assumes all risks for any damages or losses arising from any use of this information , except to the extent such damages or losses cannot be limited or excluded by applicable law .
past financial performance is no guarantee of future results. .
label: 0.34024000000000004
qa: answer: 34%
explanation: to find the percentage of the purchase was cash one must divide the amount in cash paid for the purchase by the total cost of the purchase .
ann_table_rows: 5
ann_text_rows: 14
steps: op: divide2-1
arg1: 2094800
arg2: 6156900
res: 34%
program: divide(2094800, 6156900)
gold_inds: table_5: cash portion of consideration the total estimated purchase price of $ 2094800 is $ 6156900 ;
text_14: ( i ) purchase price the purchase price is as follows: .
exe_ans: 0.34024000000000004
tfidftopn: table_4: cash portion of consideration The direct acquisition costs of $ 2094800 is 24200 ;
program_re: divide(2094800, 6156900)
model_input: text_8
the aggregate purchase price of approximately $ 6156900 included $ 2094800 in cash ; 132038 shares of hologic common stock at an estimated fair value of $ 3671500 ; 16465 of fully vested stock options granted to cytyc employees in exchange for their vested cytyc stock options , with an estimated fair value of approximately $ 241400 ; the fair value of cytyc 2019s outstanding convertible notes assumed in the merger of approximately $ 125000 ; and approximately $ 24200 of direct acquisition costs .
table_0
cash portion of consideration the cash portion of consideration of $ 2094800 is $ 2094800 ;
table_5
cash portion of consideration the total estimated purchase price of $ 2094800 is $ 6156900 ;